Tianjin Zhongxin Pharmaceutical Group Corp Ltd Market Cap ($3.51 Billion)
Market Cap & Net Worth: Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)
Tianjin Zhongxin Pharmaceutical Group Corp Ltd market cap. Tianjin Zhongxin Pharmaceutical Group Corp Ltd (SHG:600329) has a market capitalization of $3.51 Billion (CN¥24.01 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #4321 globally and #632 in its home market, demonstrating a 5.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tianjin Zhongxin Pharmaceutical Group Corp Ltd's stock price CN¥42.12 by its total outstanding shares 570094356 (570.09 Million). Also see 600329 cash flow metrics for how efficiently the company converts equity into cash flow.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Market Cap History (2015–2026)
Tianjin Zhongxin Pharmaceutical Group Corp Ltd market cap history from 2015 to 2026. Data shows growth from $1.56 Billion to $3.51 Billion (8.67% CAGR). Check 600329 live share price for real-time trading data and today's change.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Tianjin Zhongxin Pharmaceutical Group Co to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.35x
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap is 0.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.15x
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap is 1.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.56 Billion | $7.08 Billion | $451.44 Million | 0.22x | 3.47x |
| 2016 | $1.31 Billion | $6.24 Billion | $423.60 Million | 0.21x | 3.08x |
| 2017 | $1.12 Billion | $5.69 Billion | $476.08 Million | 0.20x | 2.36x |
| 2018 | $948.43 Million | $6.36 Billion | $561.68 Million | 0.15x | 1.69x |
| 2019 | $1.07 Billion | $6.99 Billion | $625.57 Million | 0.15x | 1.72x |
| 2020 | $1.38 Billion | $6.60 Billion | $661.70 Million | 0.21x | 2.09x |
| 2021 | $2.51 Billion | $6.91 Billion | $769.14 Million | 0.36x | 3.26x |
| 2022 | $2.38 Billion | $8.25 Billion | $861.79 Million | 0.29x | 2.76x |
| 2023 | $2.81 Billion | $8.22 Billion | $986.71 Million | 0.34x | 2.84x |
| 2024 | $2.57 Billion | $7.31 Billion | $2.23 Billion | 0.35x | 1.15x |
Competitor Companies of 600329 by Market Capitalization
Companies near Tianjin Zhongxin Pharmaceutical Group Corp Ltd in the global market cap rankings as of November 8, 2026. Also see 600329 total assets for a full breakdown of the balance sheet.
Key companies related to Tianjin Zhongxin Pharmaceutical Group Corp Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Tianjin Zhongxin Pharmaceutical Group Corp Ltd (2015–2026)
Market capitalization of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 2015 to today. Between 2015 and today, Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap moved from $1.56 Billion to $ 3.51 Billion, with a yearly change of 8.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.51 Billion | -7.67% |
| 2025 | CN¥3.81 Billion | +48.12% |
| 2024 | CN¥2.57 Billion | -8.47% |
| 2023 | CN¥2.81 Billion | +18.15% |
| 2022 | CN¥2.38 Billion | -5.20% |
| 2021 | CN¥2.51 Billion | +81.66% |
| 2020 | CN¥1.38 Billion | +28.59% |
| 2019 | CN¥1.07 Billion | +13.13% |
| 2018 | CN¥948.43 Million | -15.56% |
| 2017 | CN¥1.12 Billion | -14.02% |
| 2016 | CN¥1.31 Billion | -16.52% |
| 2015 | CN¥1.56 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Tianjin Zhongxin Pharmaceutical Group Corp Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.51 Billion USD |
| MoneyControl | $3.51 Billion USD |
| MarketWatch | $3.51 Billion USD |
| marketcap.company | $3.51 Billion USD |
| Reuters | $3.51 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more